Physician profile
Macy Ball
NPI 1558989723
$4,488.63
in general payments reported to CMS, 2019-2025
22 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,239 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $873.43 | 2021 | |
| Lilly USA, LLC | $450.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $361.64 | 2021-2025 | Breztri |
| Mannkind Corporation | $346.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.69 | 2021 | |
| Esperion Therapeutics, INC. | $294.77 | 2021 | |
| Dexcom, INC. | $294.18 | 2021 | |
| Amgen INC. | $228.92 | 2021 | |
| Medtronic, INC. | $174.53 | 2021 | |
| Abbvie INC. | $169.85 | 2021 | |
| Zealand Pharma US, INC. | $162.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $140.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $136.76 | 2025 | |
| Xeris Pharmaceuticals, INC. | $135.48 | 2021 | |
| Merck Sharp & Dohme LLC | $131.72 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $97.73 | 2021 | |
| Amarin Pharma, INC. | $67.45 | 2021 | |
| Abbott Laboratories | $40.72 | 2021 | |
| Alexion Pharmaceuticals, INC. | $31.09 | 2021 | |
| Insulet Corporation | $20.66 | 2021 | |
| Tandem Diabetes Care, INC. | $19.07 | 2021 | |
| Radius Health, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macy Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.